A Registry Study of Permanent Breast Seed Implant

Breast Neoplasms Clinical Trial

Official title:

A Multicentre Registry Study of Permanent Breast Seed Implant (PBSI) for Early Stage Breast Cancers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01106521
• Other study ID #: PBSI Registry
• Status: Completed
• Phase: N/A
• Start date: March 2009
• Est. completion date: January 19, 2018

Study information

• Verified date: October 2021
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Women found to have early stage breast cancer will have their cancer surgically removed followed by radiation treatment to the entire breast, five times per week for several weeks. The radiation treatment prevents the cancer from growing back but creates skin burns. Several studies have showed that it is nor necessary treating the whole breast.

The investigators team has pioneered a new therapy realizing the permanent implantation of tiny radioactive seeds into the surgical cavity in a single one hour procedure under light anesthesia. Patients live a normal life while receiving the radiation treatment. The results of a first clinical trial on 67 patients shows that the treatment is well tolerate and efficient. The purpose of the study is to offer the treatment in several places and to increase the cohort of patient to 420 to capture rare complications if any.

Description:

For early stage breast cancer, accelerated partial breast irradiation is an alternative treatment option to whole breast irradiation after breast conserving surgery. Our group has previously reported results of a Phase I/II study of permanent breast seed implant (PBSI) using palladium-103 seeds as an alternative to whole breast radiotherapy for well selected breast cancer patients. The procedure is realised in a single session under light sedation and local freezing. After a median FU of 54 months no patients has recurred on a cohort of 67 patients, and acute of delayed side effect compared favourably to external beam radiotherapy.

Yet this study was a single centre study and the sample size did not allow evaluating appropriately the risk of serious adverse events (SAE). The current study propose evaluating SAE on a multicentre and larger cohort of 420 patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 420
• Est. completion date: January 19, 2018
• Est. primary completion date: January 19, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• A confirmed histological diagnosis of invasive breast carcinoma

• Treated by breast conserving surgery with axillary node dissection (with a minimum of 6 nodes sampled) or sentinel lymph node biopsy

• Surgical margins clear over or equal to 2 mm

• A maximum tumor size of 3 cm

• Age >= 50 years old

• ECOG performance status of 0 or 1

• Informed consent signed

Exclusion Criteria:

• Previous history of cancer other than curable skin SCC or Tis or T1 cervix

• Patient receiving anti-coagulant that cannot be stopped two weeks prior PBSI

• Autoimmune disorder

• Diabetes insulin-dependant

• Pregnancy

• Breast implants

• Psychiatric or addictive disorder that would preclude attending follow-up

• Post-operative breast infection

• Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy proven benign)

• Lobular features on histology (pure or mixed) or sarcoma histology

• Node positive on axillary dissection or in the sentinel lymph node biopsy

• Extensive in situ carcinoma

• Multicentric disease (in more than one quadrant or separated by 2 cm or more)

• Paget's disease of the nipple

• Metastases

• Patients presenting a post-surgical fluid cavity = 2.5 cm in diameter in any dimension as determined on the planning US

• Clear delineation of the target volume on CT is not possible

• Having a volume to be implanted over 120cc

• Having a target volume too close to skin such that the 85% isodose overlaps the skin surface)

• Having a target volume too close to the chest wall, such that there is a risk of perforating the chest wall

Related Conditions & MeSH terms

• Breast Neoplasms

Intervention

Radiation:
• Permanent breast seeds implant
Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT

Locations

Country	Name	City	State
Canada	Sunnybrook Odette Cancer Centre	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre	British Columbia Cancer Agency, West Penn Allegheny Health System

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Keller B, Sankreacha R, Rakovitch E, O'brien P, Pignol JP. A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):358-65. — View Citation

Keller BM, Pignol JP, Rakovitch E, Sankreacha R, O'Brien P. A radiation badge survey for family members living with patients treated with a (103)Pd permanent breast seed implant. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):267-71. Epub 2007 Oct 29. — View Citation

Pignol JP, Keller B, Rakovitch E, Sankreacha R, Easton H, Que W. First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):176-81. Epub 2005 Sep 22. — View Citation

Pignol JP, Rakovitch E, Keller BM, Sankreacha R, Chartier C. Tolerance and acceptance results of a palladium-103 permanent breast seed implant Phase I/II study. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1482-8. doi: 10.1016/j.ijrobp.2008.06.1945. Epu — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serious Adverse Events	Serious Adverse Events (SAE) is an unintended sign, symptom, or syndrome illness that occurs during the period of observation in the clinical study and that is life threatening or result in death. SAE will be coded using the NCI CTC V3.0 scale and corresponds to grade 4 or 5 signs or symptoms.	Initial and then yearly up to 5 years
Secondary	Breast cancer local recurrence	Ipsilateral in-breast or chest wall recurrence is defined as evidence of invasive or in situ breast cancer (except LCIS) in the ipsilateral breast. Patients will have a biopsy of the suspicious lesion to confirm the diagnosis with documentation of the location.	Yearly up to 10 years
Secondary	Regional recurrence	Regional recurrence is defined as the development of tumor in regional nodes as well as the soft tissue of the ipsilateral axilla after axillary dissection. The regional recurrence is suspected on imaging and/or clinical symptoms and must be documented with fine needle aspiration. Also the localisation of the nodal recurrence must be reported (internal mammary chain, supra-clavicular area or axilla).	Yearly up to 10 years
Secondary	Metastases	Distant recurrence is defined as evidence of tumor in any area of the body. The metastasis recurrence should be proved by appropriate imaging, biopsy or fine needle aspiration	Yearly up to 10 years
Secondary	PBSI side effects	Any toxicity related to the radiation treatment, including skin and subcutaneous, or any other organ in case of seed migration will be coded using the NCI common toxicity criteria version 3.0 scale.	After procedure
Secondary	PBSI side effects	Any toxicity related to the radiation treatment, including skin and subcutaneous, or any other organ in case of seed migration will be coded using the NCI common toxicity criteria version 3.0 scale.	At 2 months
Secondary	PBSI side effect	Any toxicity related to the radiation treatment, including skin and subcutaneous, or any other organ in case of seed migration will be coded using the NCI common toxicity criteria version 3.0 scale.	At 6 months
Secondary	PBSI side effect	Any toxicity related to the radiation treatment, including skin and subcutaneous, or any other organ in case of seed migration will be coded using the NCI common toxicity criteria version 3.0 scale. Fat necrosis will be diagnosed either by mammography or clinically (prolonged indurations and pain in the area of seeds implantation without evidence of infection).	Yearly up to 10 years
Secondary	Cosmetic outcome	Cosmetic results will be evaluated at each follow-up visit by the treating radiation oncologist. An excellent cosmetic result score is assigned when the treated breast looked essentially the same as the contralateral breast (as it relates to radiation effects). A good cosmetic score is assigned for minimal but identifiable radiation effects of the treated breast. A fair score means significant radiation effects were readily observable. A poor score is used for severe sequelae of breast tissue secondary to radiation effects.	Yearly up to 10 years
Secondary	Survival	Patient survival, either free of cancer or with disease present will be recorded at follow-up appointments.	Yearly up to 10 years